Cyclic Peptides Patents (Class 530/317)
-
Publication number: 20130071424Abstract: The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.Type: ApplicationFiled: September 12, 2012Publication date: March 21, 2013Applicant: NEW YORK UNIVERSITYInventors: Timothy CARDOZO, Xiangpeng KONG, Susan ZOLLA-PAZNER
-
Patent number: 8399611Abstract: The template-fixed ?-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with X being Ala or Tyr, have CXCR4 antagonizing properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immuno suppression; or for treating inflammation, or, in particular, for stem cell mobilization of peripheral blood stem cells and/or mesenchymal stem cell (MSC) and/or other stem cells which retention depend on the CXCR4-receptor.Type: GrantFiled: February 28, 2007Date of Patent: March 19, 2013Assignees: Polyphor Ltd., Universitaet ZuerichInventors: Daniel Obrecht, Frank Gombert, Steven J. Demarco, Christian Ludin, Jan Wim Vrijbloed, Kerstin Moehle, John-Anthony Robinson, Reshmi Mukherjee, Heiko Henze, Barbara Romagnoli
-
Publication number: 20130065837Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.Type: ApplicationFiled: March 21, 2011Publication date: March 14, 2013Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Lori Hazlehurst, Mark Mclaughlin, Priyesh Jain, William S. Dalton
-
Publication number: 20130045922Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these pep tide analogs and uses thereof.Type: ApplicationFiled: January 27, 2011Publication date: February 21, 2013Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Avner Adini, Robert D'Amato
-
Publication number: 20130039948Abstract: The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCR??-CD3??-CD3??-?? signaling complex. Yet more specifically, the peptides act on the TCR?/CD3??/?? signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions.Type: ApplicationFiled: September 30, 2010Publication date: February 14, 2013Applicant: SIGNABLOK, INC.Inventor: Alexander B. Sigalov
-
Patent number: 8372799Abstract: A protein which is composed N-terminally of one or several C-terminal parts of the amino acid sequence of the mature tumor necrosis factor and C-terminally of one or several N-terminal parts of the amino acid sequence of the mature tumor necrosis factor, which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas.Type: GrantFiled: December 12, 2008Date of Patent: February 12, 2013Assignee: Apeptico Forschung und Entwicklung GmbHInventors: Bernhard Fischer, Rudolf Lucas
-
Patent number: 8367621Abstract: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing ?v integrins.Type: GrantFiled: January 16, 2009Date of Patent: February 5, 2013Assignee: Sanford-Burnham Medical Research InstituteInventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara
-
Publication number: 20130030149Abstract: The process described herein discloses purification process of a secondary metabolite produced by fermentation route. The process involves selective removal of impurities at various stages of washings, charcoalization followed by crystallization. The product is closely related to class of echinocandins and is found to be potent antifungal compound & a key ingredient in the synthesis of antifungal drugs.Type: ApplicationFiled: May 17, 2010Publication date: January 31, 2013Inventors: Kushal Rastogi, Onkar Prakash Santan, Nitin Sopanrao Patil, Rakesh Bhaiyyaram Mendhe
-
Publication number: 20130028939Abstract: The invention relates to a nucleic acid molecule selected from the group comprising a) a nucleic acid molecule having one of the nucleotide sequences presented in SEQ ID:NO 4 to SEQ ID:NO 8, b) a nucleic acid molecule that codes for a peptide having one of the amino acid sequences presented in SEQ ID:NO 12 to SEQ ID:NO 16, c) a nucleic acid molecule, the complementary strand of which hybridizes to a nucleic acid molecule according to a) or b) and which codes for a peptide having antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which deviates from the nucleotide sequence of a nucleic acid molecule according to c) because of the degenerated genetic code.Type: ApplicationFiled: November 20, 2010Publication date: January 31, 2013Applicant: CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIELInventor: Joachim Grötzinger
-
Publication number: 20130022573Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.Type: ApplicationFiled: December 8, 2011Publication date: January 24, 2013Applicants: Selcia Limited, Gilead Sciences, Inc.Inventors: Todd Appleby, Hans G. Fliri, Andrew J. Keats, Linos Lazarides, Richard L. Mackman, Simon N. Pettit, Karine G. Poullennec, Jonathan Sanvoisin, Victoria A. Steadman, Gregory M. Watt
-
Publication number: 20130023464Abstract: Peptide analogues of PYY, compositions comprising said analogues and methods of using said analogues for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as diabetes and obesity, and for a reduction in appetite, reduction in food intake or reduction of calorie intake in a subject.Type: ApplicationFiled: January 27, 2011Publication date: January 24, 2013Inventor: Stephen Robert Bloom
-
Publication number: 20130023483Abstract: Specific template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are ?-amino acid residues connected from the carbonyl (C?O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these ?-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilisation of stem cells.Type: ApplicationFiled: February 5, 2010Publication date: January 24, 2013Applicant: POLYPHOR AGInventors: Frank Otto Gombert, Alexander Lederer, Daniel Obrecht, Barbara Romagnoli, Christian Bisang, Christian Ludin
-
Patent number: 8357654Abstract: A compound of formula (I) is described, wherein Y represents a macrocycle, the ring of which has 9 to 36 atoms, and is functionalized by three amine or COOH functions; Rc represents a group of formula H—Xa—Xb—Xc—Xd—Xe—(Xf)i—, i represents 0 or 1, Xa is in particular lysine, arginine, or ornithine residues, Xb is in particular glycine, asparagine, L-proline or D-proline residues, Xc and Xd are in particular tyrosine, phenylalanine or 3-nitrotyrosine residues, Xe and Xf are in particular amino acid residues: NH2—(CH2)n—COOH, n ranging from 1 to 10, or NH2—(CH2—CH2—O)m—CH2CH2COOH, m ranging from 3 to 6, provided that at least one of the amino acid residues Xa, Xb, Xc and Xd is different from the corresponding amino acid in the sequence of the natural CD40 143Lys-Gly-Tyr-Tyr146 fragment(SEQ ID NO: 1).Type: GrantFiled: December 15, 2005Date of Patent: January 22, 2013Assignee: Centre National de la Recherche ScientifiqueInventors: Gilles Guichard, Sylvie Victorine Lucienne Fournel, Olivier Chaloin, Nathalie Trouche, Sêbastien Wieckowski, Johan Hoebeke
-
Publication number: 20130018171Abstract: The present invention relates to a method for the purification of cyclopeptides of general formula (3) by means of a silicate.Type: ApplicationFiled: March 22, 2011Publication date: January 17, 2013Applicant: DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V.Inventor: Robertus Mattheus De Pater
-
Patent number: 8354372Abstract: This invention relates to an oral or enteral pharmaceutical preparation comprising at least one synthetically cyclised alpha-conotoxin peptide having an amide cyclised backbone such that the peptide has no free N- or C-terminus, said peptide having the ability to inhibit a nicotinic acetylcholine receptor and comprising four cysteine residues bonded in pairs to form two disulfide bonds, wherein the N-terminus of the corresponding linear/non-cyclised conotoxin peptide is linked to the C-terminus by a peptide linker, in a vehicle which is pharmaceutically suitable for oral or enteral administration.Type: GrantFiled: April 3, 2007Date of Patent: January 15, 2013Assignee: The University of QueenslandInventors: Richard Clark, David James Craik
-
Publication number: 20130012432Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: February 28, 2011Publication date: January 10, 2013Applicant: Novo Nordisk A/SInventors: Kilian Waldemar Conde-Frieboes, Jane Spetzler, Ulrich Sensfuss, Birgitte Schjellerup Wulff, Henning Thoegersen, Jens Christian Norrild
-
Patent number: 8349797Abstract: The present invention is directed to a compound according to formula, (R2R3)-B1-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-A11-A12-A13-B2-B3-R1, that act as ligands for one or more of the melanocortin receptors, the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to pharmaceutical compositions useful therefore comprising said peptides.Type: GrantFiled: July 10, 2006Date of Patent: January 8, 2013Assignee: IPSEN Pharma S.A.S.Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
-
Publication number: 20130005647Abstract: A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent.Type: ApplicationFiled: December 22, 2010Publication date: January 3, 2013Applicants: University College Cork, National University of Ireland, Teagasc, The Agriculture and Food Development AuthorityInventors: Colin Hill, Paul Cotter, Paul R. Ross, Desmond Field
-
Publication number: 20130005644Abstract: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.Type: ApplicationFiled: January 12, 2012Publication date: January 3, 2013Applicant: PROMICS PTY LIMITEDInventors: David FAIRLIE, Stephen Maxwell Taylor, Angela Monique Finch, Allan Wong
-
Publication number: 20130005648Abstract: The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.Type: ApplicationFiled: October 29, 2010Publication date: January 3, 2013Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Lilia I. Melnik, Robert F. Garry, Cindy A. Morris
-
Patent number: 8343477Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R3, R?3, R4, R6, R?, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: January 1, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Stanley D'Andrea, Zhizhen Barbara Zheng, Paul Michael Scola
-
Patent number: 8338565Abstract: Disclosed herein are macrocyclic compounds and methods for their synthesis and use. In particular, macrocyclic compounds are disclosed that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.Type: GrantFiled: August 20, 2009Date of Patent: December 25, 2012Assignee: Ensemble Therapeutics CorporationInventors: Jinbo Lee, Julian F. Bond, Nicholas Terrett, Frank G. Favaloro, Jr., Daniel Wang, Timothy F. Briggs, Benjamin Adam Seigal, Wei-Chuan Sun, Stephen P. Hale
-
Patent number: 8329658Abstract: This invention provides compounds of general formula (I): wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus and/or human immunodeficiency virus.Type: GrantFiled: October 2, 2006Date of Patent: December 11, 2012Assignee: Scynexis, Inc.Inventors: David Renwick Houck, Keqiang Li
-
Patent number: 8329859Abstract: The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature.Type: GrantFiled: January 22, 2010Date of Patent: December 11, 2012Assignee: Sanford-Burnham Medical Research InstituteInventors: Pirjo Laakkonen, Kimmo Porkka, Jason A. Hoffman, Erkki I. Ruoslahti
-
Publication number: 20120309676Abstract: Described are certain salts of certain lantibiotic compounds, pharmaceutical compositions comprising the same and use of the salts and compositions for the treatment of microbial infection, particularly Methicillin-resistant Staphylococcus aureus (MRSA) infection. The salts have an aqueous solubility of 2.5 mg/mL or more.Type: ApplicationFiled: February 1, 2011Publication date: December 6, 2012Inventors: Sjoerd Nicolaas Wadman, Antony Nicholas Appleyard
-
Patent number: 8324428Abstract: The present invention provides novel stabilized crosslinked compounds having secondary structure motifs, libraries of these novel compounds, and methods for the synthesis of these compounds libraries thereof. The synthesis of these novel stabilized compounds involves (1) synthesizing a peptide from a selected number of natural or non-natural amino acids, wherein said peptide comprises at least two moieties capable of undergoing reaction to promote carbon-carbon bond formation; and (2) contacting said peptide with a reagent to generate at least one crosslinker and to effect stabilization of a secondary structure motif. The present invention, in a preferred embodiment, provides stabilized p53 donor helical peptides. Additionally, the present invention provides methods for disrupting the p53/MDM2 binding interaction comprising (1) providing a crosslinked stabilized ?-helical structure; and (2) contacting said crosslinked stabilized ?-helical structure with MDM2.Type: GrantFiled: June 8, 2010Date of Patent: December 4, 2012Assignee: President and Fellows of Harvard CollegeInventors: Gregory L. Verdine, Christian E. Schafmeister
-
Patent number: 8324162Abstract: This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have diuretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing diuretic and/or natriuretic activities within a mammal.Type: GrantFiled: August 8, 2007Date of Patent: December 4, 2012Assignee: Mayo Foundation for Medical Education and ResearchInventors: Robert D. Simari, Shuchong Pan, John C. Burnett, Jr., Horng H. Chen
-
Patent number: 8324154Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.Type: GrantFiled: December 21, 2006Date of Patent: December 4, 2012Assignee: Novabiotics, Ltd.Inventor: Deborah O'Neil
-
Publication number: 20120302728Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.Type: ApplicationFiled: February 1, 2011Publication date: November 29, 2012Inventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
-
Publication number: 20120302493Abstract: The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.Type: ApplicationFiled: February 2, 2012Publication date: November 29, 2012Applicant: Promics PTY LimitedInventors: Stephen Maxwell Taylor, Ian Alexander Shiels, David Fairlie, Darren March, Michael W. Whitehouse
-
Publication number: 20120294801Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.Type: ApplicationFiled: April 16, 2012Publication date: November 22, 2012Applicant: Yeda Research and Development Co., Ltd.Inventors: Avigdor Scherz, Yoram Salomon, Efrat Rubinstein, Alexander Brandis, Doron Eren, Karin Neimann
-
Publication number: 20120295842Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.Type: ApplicationFiled: December 29, 2011Publication date: November 22, 2012Inventors: Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, David J. Grampovnik, Brian Green, Timothy Middleton, Todd Hopkins, Yat Sun Or
-
Patent number: 8304385Abstract: The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.Type: GrantFiled: November 14, 2008Date of Patent: November 6, 2012Assignee: Enanta Pharmaceuticals, Inc.Inventors: Ying Sun, Dong Liu, Yat Sun Or, Zhe Wang
-
Patent number: 8304382Abstract: The present invention refers to synthetic, cyclic peptides containing a sequence of 13 L-amino acids in their primary structure which present anti-inflammatory and antiallergic activities, useful for the treatment of acute or chronic inflammation and/or allergies, being particularly useful for the treatment of acute or chronic allergic asthma. The invention also describes a pharmaceutical composition containing said peptides, its use and a method to treat or prevent acute and/or chronic inflammatory and/or allergic disorders.Type: GrantFiled: July 19, 2007Date of Patent: November 6, 2012Assignees: Cristalia Productos Quimicos Farmaceuticos Ltda., Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FAPESPInventors: Mônica Ferreira, Carla Silva, Daniel Pimenta, Fernanda Portaro, Katia Conceição, Marilene Demasi
-
Patent number: 8299212Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.Type: GrantFiled: September 20, 2006Date of Patent: October 30, 2012Assignee: Thrasos Therapeutics, Inc.Inventors: William D. Carlson, Peter C. Keck, Dattatreymurty Bosukonda, Philippe Bey
-
Patent number: 8299209Abstract: Pharmaceutical compositions comprising a somastatin analogue in the form of a liquid formulation for parenteral administration are disclosed.Type: GrantFiled: January 26, 2009Date of Patent: October 30, 2012Assignee: Novartis AGInventors: Olivier Lambert, Katrin Moser
-
Publication number: 20120270807Abstract: The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the compounds. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.Type: ApplicationFiled: October 22, 2010Publication date: October 25, 2012Inventors: Éric Marsault, Olivier Leogane, Axel Mathieu, Sylvie Beaubien
-
Publication number: 20120264693Abstract: Compounds capable of modulating intracellular gap junctional communication, as well as their use in the treatment of diseases associated with impaired gap junction intracellular communication (GJIC) 1 are disclosed.Type: ApplicationFiled: June 11, 2010Publication date: October 18, 2012Applicants: Zealand Pharma A/S, The Regents of the University of Michigan, The Research Foundation of State Univesity of New YorkInventors: Mario Delmar, Steven M. Taffet, Wanda Coombs, Vandana Verma, Bjarne Due Larsen
-
Publication number: 20120258077Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: June 14, 2012Publication date: October 11, 2012Applicant: Theraclone Sciences, Inc.Inventors: Matthew Moyle, Jennifer Mitcham
-
Publication number: 20120252730Abstract: Peptides and cyclized analogs thereof that are useful as platelet aggregation inhibitors in the treatment of cardiac disease, including acute coronary syndrome are disclosed.Type: ApplicationFiled: September 2, 2010Publication date: October 4, 2012Applicant: UNIVERSITY OF CHICAGOInventors: Milan Mrksich, Juan Sanchez-Cortes
-
Patent number: 8278322Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.Type: GrantFiled: July 28, 2006Date of Patent: October 2, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: M. Katharine Holloway, Nigel J. Liverton, John A. McCauley, Michael T. Rudd, Joseph P. Vacca, Steven W. Ludmerer, David B. Olsen
-
Publication number: 20120244070Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.Type: ApplicationFiled: March 25, 2011Publication date: September 27, 2012Inventors: Zheng-Rong LU, Xueming Wu
-
Publication number: 20120238507Abstract: Disclosed are short chain peptides that are constrained to adopt an alpha helicial conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides. Also disclosed is the use of these peptides for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. The peptides find use in mimicking naturally occurring peptides or proteins or in preparing new materials.Type: ApplicationFiled: May 30, 2012Publication date: September 20, 2012Applicant: THE UNIVERSITY OF QUEENSLANDInventors: David P. Fairlie, Nicholas E. Shepherd
-
Publication number: 20120237444Abstract: The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using the radioiodinated BTMs.Type: ApplicationFiled: December 10, 2010Publication date: September 20, 2012Inventor: Michelle Avory
-
Publication number: 20120231996Abstract: The invention provides a cyclomonomer having actin-binding activity. The cyclomonomer is of utility for the study of the molecular biology of actin polymerization. The cyclomonomer is also useful for the study of and treatment of the toxic effects of Amanita sp. poisoning.Type: ApplicationFiled: June 9, 2011Publication date: September 13, 2012Inventors: R. Scott Lokey, Laura A. Schuresko
-
Publication number: 20120232247Abstract: The present invention relates to synthetic processes useful in the preparation of macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus NS3 protease and have application in the treatment of conditions caused by the hepatitis C virus. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.Type: ApplicationFiled: August 26, 2010Publication date: September 13, 2012Inventors: Zhiguo Jake Song, Yaling Wang, David M. Tellers, Laura M. Artino, David R. Lieberman
-
Publication number: 20120226018Abstract: The present invention relates to a novel process for the synthesis of the melanocortin analog, Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, using solution-phase peptide chemistry.Type: ApplicationFiled: November 15, 2010Publication date: September 6, 2012Applicant: IPSEN PHARMA, S.A.S.Inventor: Zheng Xin Dong
-
Publication number: 20120225828Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Wei Yang, Yi-Qun Shi
-
Patent number: 8258098Abstract: The present invention relates to combinations of aplidine or aplidine analogues with other titumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.Type: GrantFiled: February 28, 2007Date of Patent: September 4, 2012Assignee: Pharma Mar, S.A.Inventors: Glynn Thomas Faircloth, Pablo Manuel Aviles Marin, Doreen LePage, Jesus San Miguel Izquierdo, Atanasio Pandiella
-
Patent number: RE44022Abstract: The invention relates to cyclopeptides, the method of their preparation and their utilization as inhibitors or activators of angiogenesis. These cyclopeptides comprise contain the following peptide sequence: -Arg-Ile-Lys-Pro-His-Gln-Gly- ??(SEQ ID NO: 1). They can be used in systems for inhibition of angiogenesis that comprises include a support (1), to which the cyclopeptide is affixed by means of coupled via an organic spacer arm (3) that may be provided with a moiety (4) capable of being spliced cleaved by an enzyme system.Type: GrantFiled: October 2, 2001Date of Patent: February 19, 2013Assignees: Commissariat a l'Energie Atomique, Universite Victor Sagalen Bordeaux 2, Universite de Bordeaux 1Inventors: Andreas Bikfalvi, Juliette Boulard, Antonin Boulard, Liliane Dequaire, Romane Boulard, Sara Boulard, Julie Deleris, Christiane Deleris, Marie Deleris